TPST

Tempest Therapeutics, Inc. · NASDAQ

Sector Health Technology
Industry Pharmaceuticals: Major
Website empesttx.com
Employees(FY) 19
ISIN US87978U1088

Performance

-14.74%

-17.74%

-49.53%

-75.03%

-83.83%

YTD

-80.66%

Profile

Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. Tempest Therapeutics, Inc. is headquartered in Brisbane, California.

Advanced Technical Analysis

Technical Analysis of TPST 2024-12-20

The stock indicators reflect a bearish sentiment overall, with a Moving Average Score of 10 indicating strong downward momentum, an Oscillators Score of 40 suggesting a neutral stance, and a Technical Score of 25 reinforcing the bearish outlook. This combination signals caution for potential investors, as the prevailing trend appears to be negat...

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of TPST

Stock Rank

Recent News & Updates

2024-12-06 03:30
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)(Globenewswire)
2024-12-05 08:00
A Reverse Aging Gurus Trail of Failed Businesses(Yahoo Finance)
2024-11-25 03:30
Tempest to Participate in the Piper Sandler 36th Annual Healthcare Conference(Globenewswire)
2024-11-12 03:21
Tempest Reports Third Quarter 2024 Financial Results and Provides Business Update(Globenewswire)
2024-11-11 19:00
Tempest Receives FDA Study May Proceed for Pivotal Phase 3 Trial of Amezalpat Combination Therapy for the Treatment of First-Line Hepatocellular Carcinoma(Globenewswire)
2024-10-09 19:01
Tempest Announces Agreement with Roche to Support Advancement of Amezalpat Combination Therapy into First-Line Hepatocellular Carcinoma Pivotal Trial(Globenewswire)
2024-10-09 19:00
Tempest Extends Limited Duration Stockholder Rights Plan(Globenewswire)
2024-09-20 04:30
Tempest Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)(Globenewswire)
2024-09-17 20:00
Tempest Further Strengthens Leadership Team with Appointment of Sheldon Mullins as Vice President, Regulatory Affairs(Globenewswire)
2024-09-04 20:00
Tempest to Present at the H.C. Wainwright 26th Annual Global Investment Conference(Globenewswire)
2024-08-23 04:30
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)(Globenewswire)
2024-08-20 20:00
Tempest Announces the Appointment of Troy M. Wagner as Vice President of Quality Assurance(Globenewswire)
2024-08-14 20:00
Tempest Announces Successful End-of-Phase 2 Meeting with FDA for Amezalpat (TPST-1120) to Treat First-Line Hepatocellular Carcinoma(Globenewswire)
2024-08-08 04:56
Tempest Reports Second Quarter 2024 Financial Results and Provides Business Update(Globenewswire)
2024-06-19 20:13
Why Is Tempest Therapeutics (TPST) Stock Up 45% Today?(Investorplace)
2024-06-19 20:00
Tempest Unveils New Survival Data for Amezalpat (TPST-1120) in Randomized First-Line HCC Study Demonstrating a Six-Month Improvement over Control Arm(Globenewswire)
2024-06-19 19:28
Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday(Investorplace)
2024-06-18 06:22
Tempest to Report New Data from Global Randomized Combination Study of Amezalpat (TPST-1120) in First-Line Hepatocellular Carcinoma(Globenewswire)
2024-06-06 16:30
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)(Globenewswire)
2024-05-20 20:00
Tempest to Participate in Upcoming Investor Conferences(Globenewswire)
2024-05-09 04:29
Tempest Reports First Quarter 2024 Financial Results and Provides Business Update(Globenewswire)
2024-04-26 04:05
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)(Globenewswire)
2024-04-08 20:00
Tempest Reports New Preclinical Data for TPST-1120 in RCC at the AACR Annual Meeting(Globenewswire)
2024-04-03 20:00
Tempest Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications(Globenewswire)
2024-03-19 09:53
TPST Stock Earnings: Tempest Therapeutics Beats EPS for Q4 2023(Investorplace)
2024-03-19 04:25
Tempest Reports Year End 2023 Financial Results and Provides Business Update(Globenewswire)
2024-03-11 20:00
Tempest Presents New Data at the SITC 2024 Spring Scientific Meeting Supporting Potent Anti-tumor Activity of TPST-1120 in Multiple Cancer Types(Globenewswire)
2024-03-05 03:30
Tempest Announces Upcoming Presentation of Preclinical Data for TPST-1120 in Renal Cell Carcinoma at the AACR Annual Meeting(Globenewswire)
2024-02-25 19:00
Tempest to Present at the 44th Annual TD Cowen Healthcare Conference(Globenewswire)
2024-02-02 03:30
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)(Globenewswire)

Page 1 of 3

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.